ARTICLE | Emerging Company Profile
Tentarix turns to mix-and-match cell system for conditional multispecifics
With $50 million from Versant and Samsara, the platform company’s first program is a conditionally active IL-2 receptor agonist
October 14, 2021 12:00 PM UTC
Tentarix is streamlining production of conditionally active, multispecific biologics using a human cell-based platform that generates and screens millions of candidates in a single go.
The company, which on Thursday announced a $50 million series A round co-led by Versant Ventures and Samsara Biocapital, aims to selectively activate or inhibit signaling in specific cell types by requiring that compounds simultaneously bind multiple targets on the surfaces of those cells to have an effect. ...